(Adds details, background)
PARIS, Sept 28 (Reuters) - French healthcare company Sanofi
announced on Tuesday positive Phase I/II study
interim results for its first mRNA-based COVID-19 vaccine
candidate.
Sanofi said initial data from these results showed
neutralizing antibody seroconversion in 91%-100% of study
participants, two weeks after a second injection, across all
three dosages tested.
"These results will clearly help inform the path forward for
our mRNA development programs," said Jean-Francois Toussaint,
global head of research and development at Sanofi Pasteur.
Sanofi added that these results showed the potential behind
the Translate Bio company recently acquired by Sanofi.
Sanofi is under pressure to revive its drug pipeline and is
also eager to overcome setbacks in the COVID-19 vaccine
race.
(Reporting by Sudip Kar-Gupta, editing by Louise Heavens)